KIF5B-RET fusions in lung adenocarcinoma
Menée sur des échantillons tumoraux prélevés sur des patients américains et japonais atteints d'un adénocarcinome du poumon, cette étude identifie une fusion des gènes KIF5B et RET chez 1 à 2% des patients
We identified in-frame fusion transcripts of KIF5B (the kinesin family 5B gene) and the RET oncogene, which are present in 1–2% of lung adenocarcinomas (LADCs) from people from Japan and the United States, using whole-transcriptome sequencing. The KIF5B-RET fusion leads to aberrant activation of RET kinase and is considered to be a new driver mutation of LADC because it segregates from mutations or fusions in EGFR, KRAS, HER2 and ALK, and a RET tyrosine kinase inhibitor, vandetanib, suppresses the fusion-induced anchorage-independent growth activity of NIH3T3 cells.